Trials / Active Not Recruiting
Active Not RecruitingNCT06688123
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
A Randomized, Open-label, Treat-to-target, Parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-3167 and Insulin Glargine in Patients With Type 2 Diabetes Mellitus With Metformin Alone or in Combination With SGLT2 Inhibitors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 275 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2 subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-3167 | Dose level 1. |
| DRUG | SHR-3167 | Dose level 2. |
| DRUG | Insulin glargine | Dose level 3. |
Timeline
- Start date
- 2025-01-08
- Primary completion
- 2026-03-30
- Completion
- 2026-04-30
- First posted
- 2024-11-14
- Last updated
- 2025-11-24
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06688123. Inclusion in this directory is not an endorsement.